Drug Profile
Dupilumab - Regeneron/Sanofi
Alternative Names: Dupilumab-Sanofi/Regeneron; Dupixent; REGN-668; SAR-231893Latest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals; sanofi-aventis
- Developer Aimmune Therapeutics; Mayo Clinic; Regeneron Pharmaceuticals; Sanofi; Sanofi-Aventis GmbH
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antineoplastics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 13 receptor antagonists; Interleukin 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Asthma; Atopic dermatitis; Chronic urticaria; Eosinophilic oesophagitis; Prurigo nodularis; Rhinosinusitis
- Preregistration Chronic obstructive pulmonary disease
- Phase III Bullous pemphigoid; Pruritus; Wheezing
- Phase II/III Eosinophilic gastroenteritis
- Phase II Aspergillosis; Eczema; Milk hypersensitivity; Prostate cancer; Ulcerative colitis; Urticaria
- No development reported Allergic asthma
- Discontinued Grass pollen hypersensitivity; Peanut hypersensitivity
Most Recent Events
- 05 Mar 2024 Regeneron and Sanofi plan a phase III trial in Prurigo nodularis (In infants, In children, In adolescents) (SC) in February 2024 (NCT06293053)
- 04 Mar 2024 Discontinued - Phase-II for Rhinosinusitis (Treatment-experienced) in Spain, Russia, Portugal, South Korea, Hungary, China, Chile, Belgium, Argentina, United Kingdom, Sweden (SC)
- 23 Feb 2024 Launched for Eosinophilic oesophagitis (In adolescents, In adults) in Canada (SC)